An Israeli study has confirmed that the first dose of Pfizer’s coronavirus vaccine is 85 percent effective, raising the possibility of delaying the second dose amidst government efforts to immunize populations as soon as possible.
The vaccine developed by Pfizer and German BioNTech was found to be 85 percent effective based on a study of health workers at Israeli state hospital Sheba Medical Center, with just one shot 15 to 28 days after it was administered.
The study published in The Lancet medical journal also found that the shot was 75 percent effective in the overall reduction of infections which includes asymptomatic cases.
The report said that the findings could “provide support of delaying the second dose in countries facing vaccine shortages and scarce resources, so as to allow higher population coverage with a single dose.”
But it said that a longer study must be done to evaluate the effects of said delay to inform future policies.
Meanwhile, the companies also reported that the vaccine need not be stored in ultracold temperatures anymore, promising easier and more flexible vaccine storage and transport.